Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Microarray Patent Revoked

By Drug Discovery Trends Editor | July 26, 2012

Agilent Technologies Inc. announced a favorable legal ruling from the European Patent Office regarding Agilent’s opposition to patent EP 0853679, assigned to Affymetrix.

On Oct. 21, 2003, Agilent joined Combimatrix and Clonediag in opposing the patent, titled “Expression Monitoring by Hybridization to High Density Oligonucleotide Arrays.” Agilent opposed the breadth of the patent, particularly the patent’s broad use of the term “control probe” in connection with gene-expression microarrays. Gene-expression microarrays are part of Agilent’s portfolio of products for genetic research.

An opposition hearing was held on Sept. 12, 2006. During the hearing the patent claims were narrowed, but Agilent and Clonediag still believed them to be overbroad and vague. After the written findings were issued on May 11, 2009, Agilent appealed. An appeal hearing was held July 5, 2012, resulting in this ruling, with all EP 0853679 claims rejected and the patent revoked in totality.

“This ruling is a very positive result for Agilent’s many European gene-expression microarray customers and the entire European gene-expression community,” said Robert Schueren, Agilent vice president, Genomics. “The ruling allows customers to continue using established workflows and protocols, including control probes, without having to worry about potential patent infringement.”

Date: July 25, 2012
Source: Agilent Technologies Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50